Search clinical trials for: BI 425809 mixed with [C-14] BI425809

Total 54 results

Boehringer Ingelheim

Completed

A Study in Healthy Men to Find Out How BI 425809 is Taken up and Handled by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

A Study in Healthy Men to Measure the Amount of BI 425809 in the Blood When Taken as a Tablet

Healthy

Netherlands
Boehringer Ingelheim

Completed

BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

Alzheimer Disease

Spain, United Kingdom, Italy, United States, Canada, Germany, Greece, Austria, Norway, France, Japan, Hungary, Poland, Finland
Boehringer Ingelheim

Completed

Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia

Schizophrenia

Spain, Korea, Republic of, United Kingdom, Taiwan, United States, Austria, Italy, Germany, Poland, Japan, Canada
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1015550 is Taken up and Handled by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

A Study in Healthy People to Test if Taking Different Formulations of BI 425809 Tablets Influences the Amount of BI 425809 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Measure the Amount of BI 730357 in the Blood When Taken as a Tablet

Healthy

Netherlands
Boehringer Ingelheim

Completed

Safety, Tolerability, and Pharmacokinetics of Single Doses BI 425809

Healthy

Germany
Boehringer Ingelheim

Completed

A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Liver Problems

Hepatic Insufficiency

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1291583 is Processed in the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 730357 is Processed by the Body

Healthy

Netherlands
Boehringer Ingelheim

Recruiting

A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body

Solid Tumors

Hungary
Boehringer Ingelheim

Completed

This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia

Schizophrenia

United States, United Kingdom, Australia, Canada, France, New Zealand
Boehringer Ingelheim

Completed

Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of BI 425809 Tablets for 12 Days to Young and Elderly Healthy Male and Female Volunteers and Comparison of Pharmacokinetics of a Single Oral Dose of BI 425809 (Morning Versus Evening)

Healthy

Germany
Boehringer Ingelheim

Completed

A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Kidney Problems

Renal Insufficiency

Germany
Boehringer Ingelheim

Completed

A Study in Healthy People to Test How BI 425809 is Taken up in the Body When Taken With or Without Food

Healthy

Germany
Boehringer Ingelheim

Completed

Single Rising Dose Trial of BI 425809 for Healthy Japanese and Chinese Male Subjects

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

Pharmacokinetics and Pharmacodynamic Effect of Different Multiple Oral Doses of BI 425809

Healthy

Belgium
Boehringer Ingelheim

Recruiting

A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study

Schizophrenia

Korea, Republic of, Canada, United States, Taiwan, United Kingdom, Chile, Serbia, Brazil, China, Colombia, Germany, Greece, Italy, Japan, Mexico, Norway, Poland, Sweden, Spain, Argentina, Croatia, France, Slovakia, Denmark, Malaysia, Czechia and more
Boehringer Ingelheim

Active, not recruiting

CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia

Schizophrenia

United States, United Kingdom, Taiwan, Germany, Bulgaria, Mexico, Argentina, Denmark, Korea, Republic of, Austria, China, Belgium, Czechia, Finland, Serbia, Brazil, Portugal, Lithuania
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 690517 is Taken up and Handled by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

A Study in Healthy Men to Find Out How BI 1015550 is Taken up and Handled by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 456906 is Processed in the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1810631 is Taken up and Processed by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 764198 is Processed in the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

This Study in Healthy Men Tests How the Body Takes up BI 1467335

Healthy

Netherlands
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test Whether Bosentan Influences the Amount of BI 425809 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men and Women to Test Which Effects Donepezil and BI 425809 Have on Each Other

Healthy

Germany
Boehringer Ingelheim

Completed

Relative Bioavailability of a Single Oral Dose of BI 425809 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male Subjects

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Fluconazole Influences the Amount of BI 425809 in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men and Women to Test Which Effects Memantine and BI 425809 Have on Each Other

Healthy

Germany
Associação Fundo de Incentivo à Pesquisa
Fisher and Paykel Healthcare; Philips Respironics

Unknown

Comparison of CPAP Modalities for OSA Treatment

Obstructive Sleep Apnea

Brazil
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine

Healthy

United States
Boehringer Ingelheim

Completed

A Study in Healthy Women to Test Whether BI 425809 Influences the Amount of a Contraceptive in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test Whether BI 425809 Influences the Amount of Midazolam in the Blood

Healthy

Germany
Boehringer Ingelheim

Completed

DDI Strong CYP3A4 Inducer

Healthy

Germany
University of California, San Francisco

Withdrawn

The Effect of Buccal Infiltration Administration of Clonidine on the Success Rate of Inferior Alveolar Nerve Block

Symptomatic Irreversible Pulpitis
UroGen Pharma Ltd.

Completed

Safety and Tolerability Study Which Evaluate Intravesical Instillation With Mitomycin C Mixed With TC-3 Drug Retaining Hydrogel Device In Patients With Muscle Invasive Bladder Cancer

Carcinoma of Urinary Bladder, Invasive

Israel
Boehringer Ingelheim

Completed

Drug Drug Interaction Trial With Strong CYP3A4 Inhibitor (Itraconazole) in CYP2C19 Extensive Metabolizers and Poor Metabolizers

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

Interaction of BI 425809 With Midazolam, Warfarin, Omeprazole and Digoxin

Healthy

Germany
Jeanne Drisko, MD, CNS, FACN
University of Kansas Medical Center; Cancer Treatment Research Foundation

Completed

Treatment of Newly Diagnosed Ovarian Cancer With Antioxidants

Ovarian Cancer

United States
University of Nebraska
National Cancer Institute (NCI)

Terminated

Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma

Glioma | Glioblastoma

United States
International Partnership for Microbicides, Inc.

Completed

To Assess the Drug-drug Interaction Potential Between Dapivirine Vaginal Ring-004, Containing 25 mg of Dapivirine, and Clotrimazole 10 mg/g (1%)

HIV- Prevention
National Cancer Institute (NCI)

Completed

Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Solid Neoplasm

United States
National Cancer Institute (NCI)
NRG Oncology

Terminated

Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma

Recurrent Uterine Corpus Sarcoma | Uterine Corpus Leiomyosarcoma | Stage IIIA Uterine Sarcoma | Stage IIIB Uterine Sarcoma | Stage IIIC Uterine Sarcoma | Stage IVA Uterine Sarcoma | Stage IVB Uterine Sarcoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | Adult Diffuse Large B-Cell Lymphoma | T-Cell Non-Hodgkin Lymphoma

United States
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University

Withdrawn

SMMART Adaptive Clinical Treatment (ACT) Trial

Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Ovarian Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Recurrent... and other conditions

United States
M.D. Anderson Cancer Center

Completed

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Hematopoietic and Lymphoid Cell Neoplasm | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic Syndrome | Recurrent Acute Lymphoblastic... and other conditions

United States
National Cancer Institute (NCI)
Canadian Cancer Trials Group

Active, not recruiting

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

United States, Canada, Israel, Puerto Rico
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent T Acute Lymphoblastic Leukemia

United States

Search clinical trials for: BI 425809 mixed with [C-14] BI425809

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations